Vincent van der Noort

机构：The Netherlands Cancer Institute, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Radiotherapeutisch Instituut Friesland · ORCID：0000-0002-4910-4535

发表论文 359 篇 · 总被引 5195 次 · h-index 31

代表论文

• Neoadjuvant ipilimumab and nivolumab in resectable cutaneous squamous cell carcinoma: a randomized phase 2 trial (2025 · Nature Medicine · 被引 13)
• Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer (2026 · JAMA Oncology · 被引 12)
• Microbial Metabolic Pathways Guide Response to Immune Checkpoint Blockade Therapy (2025 · Cancer Discovery · 被引 7)
• Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis (2026 · The Lancet Oncology · 被引 4)
• Pembrolizumab plus lenvatinib as second-line treatment in patients with pleural mesothelioma (PEMMELA): cohort 2 of a single-arm, phase 2 study (2025 · The Lancet Oncology · 被引 4)
• Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus second-line for advanced breast cancer: A cost-effectiveness analysis of the phase 3 SONIA trial (2025 · European Journal of Cancer · 被引 3)